Welcome

The theme of our 7th Annual Patient-Centered Approach to Clinical Trials Conference is: Embedding Cancer Clinical Trials Research into Clinical Practice.

 Over the course of the past several years, we have made significant progress in fostering patient and patient group partnerships among researchers and stakeholders engaged in cancer clinical trials and their engagement in the clinical trial continuum.

 Our objectives this year are:

  • Lay out the case for embedding clinical trials into clinical practice
  • Educate on how embedding clinical trials into clinical practice supports and builds a learning health system
  • Explore, using the CTTI model as a foundation, how embedding clinical trials into clinical practice can be achieved in Canada
  • Gain cross stakeholder perspective and input on barriers and facilitators to moving forward

 The 7th edition of this Conference is structured as follows:

 

 
“When research data is collected separately from a clinical care setting, studies may produce results that do not reflect the real-world performance of medical products in the populations that will use them. Researchers can bridge these gaps by embedding adequate and well-controlled trials into regular clinical practice. The bigger question that remains is how best to facilitate the integration of interventional trials into clinical practice.”

CITTI 2022 




Registration Form

Sponsors
Speakers
Speakers
Alan J. Forster Image du conférencier
Anne Marie Wright Image du conférencier
Camille Leahy Image du conférencier
Dr. Angie Marsh Image du conférencier
Dr. Anne-Marie Mes-Masson Image du conférencier
Dr. Fahad Razak Image du conférencier
Dr. Francois Lamontagne Image du conférencier
Dr. Gerald Batist Image du conférencier
Dr. Henry Conter Image du conférencier
Dr. John Marshall Image du conférencier
Dr. Kelvin Chan Image du conférencier
Dr. Manoj Lalu Image du conférencier
Dr. Natalie Coburn Image du conférencier
Dr. Philippa Corrie Image du conférencier
Dr. Srinivas Murthy Image du conférencier
Dr. Stuart Nicholls Image du conférencier
Dr. Vishal Navani Image du conférencier
Karine-Iseult Ippersiel Image du conférencier
Linda Hunter Image du conférencier
Megan Bettle Image du conférencier
Nicole Yada Image du conférencier
Sara Bristol Calvert Image du conférencier
Shaneel Pathak Image du conférencier
Co-Chairs
Barry Stein Image du conférencier
Dr. Stéphanie Michaud Image du conférencier
Dr. Winson Cheung Image du conférencier
Michael Duong, Ph.D. Image du conférencier
Stephen Sundquist Image du conférencier
Agenda
01
9:00
- 9:15
9:15
- 10:00
A visionary convrsation on the evolution of Clinical Trials.
A visionary convrsation on the evolution of Clinical Trials.
10:00
- 10:40
CIHR Fall 2022 survey results. 2021-2030 Strategic Plan. CT fund overview. Setting the stage for Learning Health Systems. Setting the stage for the vision and future of embedded trials.
CIHR Fall 2022 survey results. 2021-2030 Strategic Plan. CT fund overview. Setting the stage for Learning Health Systems. Setting the stage for the vision and future of embedded trials.
10:00
- 11:20
10:40
- 11:20
Lessons learned in cancer that were taken forward and applied in the National Institute for Health & Care Research (NIHR) supported Recovery Trial. How these lessons are being applied to advance precision medicine and the cancer vaccine. What needs to happen to ensure embedded trials become reality.
Lessons learned in cancer that were taken forward and applied in the National Institute for Health & Care Research (NIHR) supported Recovery Trial. How these lessons are being applied to advance precision medicine and the cancer vaccine. What needs to happen to ensure embedded trials become reality.
11:20
- 11:45
11:45
- 12:30
Why RWE and why now? Creating “fit for purpose” RWE generation. Case studies on pilots/initiatives/learning: examples of practice data utilization in research. How O2 supports embedded trials.
Why RWE and why now? Creating “fit for purpose” RWE generation. Case studies on pilots/initiatives/learning: examples of practice data utilization in research. How O2 supports embedded trials.
12:30
- 13:30
13:45
- 14:30
Clinical trials are well controlled and the transferability of data across geographies are more 'acceptable' but RWD capture the influences of the patients' environments and ecosystems, therefore locally collected RWD is more relevant and better informs true effectiveness within the ecosystem in which the patient is treated. This outlines the need for Canada to have the infrastructure to capture and make available high quality real world data; the importance and use of Synthetic Data.
Clinical trials are well controlled and the transferability of data across geographies are more 'acceptable' but RWD capture the influences of the patients' environments and ecosystems, therefore locally collected RWD is more relevant and better informs true effectiveness within the ecosystem in which the patient is treated. This outlines the need for Canada to have the infrastructure to capture and make available high quality real world data; the importance and use of Synthetic Data.
14:30
- 16:00
CLINICAL TRIALS TRANSFORMATION INITIATIVE (CTTI) Initiative overview and the case for embedding clinical trials into clinical practice. How this new model was conceived and developed. Benefit overview. Why this is good for patients.
CLINICAL TRIALS TRANSFORMATION INITIATIVE (CTTI) Initiative overview and the case for embedding clinical trials into clinical practice. How this new model was conceived and developed. Benefit overview. Why this is good for patients.
16:00
- 16:45

A discussion of how to make research more patient-centric, with a focus on patient engagement throughout the research process.

A discussion of how to make research more patient-centric, with a focus on patient engagement throughout the research process.

16:45
- 17:00
02
9:00
- 9:15
9:15
- 9:45
Industry perspective on the future of clinical trials
Industry perspective on the future of clinical trials
9:45
- 10:45
Multi-stakeholder discussion on the needs, barriers, facilitators and benefits of embedded trials in Canada Assessing whether to embed trial elements into practice, ‘how to’ what to think about, CTTI ‘operational guidelines’ to reflect on.
Multi-stakeholder discussion on the needs, barriers, facilitators and benefits of embedded trials in Canada Assessing whether to embed trial elements into practice, ‘how to’ what to think about, CTTI ‘operational guidelines’ to reflect on.
10:45
- 11:00
11:00
- 12:00
Panel discussion led by Dr. John Marshall, Canadian lead investigator, REMAP-CAP trial (Randomized, Embedded, Multifactorial, Adaptive Platform Trial for Community Acquired Pneumonia)
Panel discussion led by Dr. John Marshall, Canadian lead investigator, REMAP-CAP trial (Randomized, Embedded, Multifactorial, Adaptive Platform Trial for Community Acquired Pneumonia)
12:00
- 12:15
12:15
- 13:30
Lunch & Working Groups
Lunch & Working Groups
13:30
- 14:15
14:15
- 15:00

Panel Discussion led by Dr. Stephanie Michaud, President & CEO of BioCanRx

Panel Discussion led by Dr. Stephanie Michaud, President & CEO of BioCanRx